Pharos iBio Co., Ltd. (KOSDAQ:388870)
South Korea · Delayed Price · Currency is KRW 8,510.00
-160.00 (-1.85%)
At close: Feb 13, 2026
Pharos iBio Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
110.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 300.00M | 243.00M | 426.32% |
| Dec 31, 2021 | 57.00M | -130.68M | -69.63% |
| Dec 31, 2020 | 187.68M | -233.43M | -55.43% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ahn-Gook Pharmaceutical | 300.96B |
| H.PIO | 257.56B |
| Daehan Nupharm | 201.59B |
| HYUNDAI BIOLAND | 129.68B |
| Sinsin Pharmaceutical | 110.29B |
| Hwail Pharmaceutical | 107.87B |
| WITHUS PHARMACEUTICAL Co.,LTD. | 102.11B |
| KOREA PHARMA | 90.11B |